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Abstract: Streptococcus mitis/oralis is a fermentative bacterium that relies on lactate dehydrogenase to balance its redox poise and keep glycolysis active. Metabolomic analysis of an in vitro–
derived daptomycin-resistant (DAP-R) S. mitis/oralis strain (351-D10) revealed differences in glucose
catabolism relative to its DAP-susceptible (DAP-S) parental strain, 351. Metabolic changes associated
with the transition to this DAP-R phenotype suggested that inhibiting glycolysis could alter DAP
susceptibility. In addition, the strong reliance of S. mitis/oralis on glycolysis for energy and biosynthetic intermediates suggested that inhibiting glycolysis would adversely affect growth and biomass
accumulation. To test these hypotheses, we used the lactate dehydrogenase inhibitor oxamic acid
(OXA) to assess its efficacy against DAP-S S. mitis/oralis strain 351 during DAP exposures in vitro
and ex vivo. As expected, OXA was growth inhibitory to S. mitis/oralis in a dose-dependent manner
in vitro; however, it did not alter in vitro DAP susceptibility profiles. In contrast, OXA did prevent
the emergence of DAP-R in an ex vivo model of simulated endocardial vegetations. These data
suggest that metabolic inhibitors directed against this fermentative bacterium with limited metabolic
capabilities could enhance killing and potentially forestall the emergence of DAP resistance.
Keywords: oxamic acid; lactate dehydrogenase; daptomycin resistance
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1. Introduction
The viridans group streptococci (VGSs) are a heterogeneous group of pathogens that
reside predominantly in the oropharynx and include the Streptococcus mitis/oralis subgroup.
This latter subgroup is the most common etiology of infective endocarditis (IE) amongst
the VGS, as well as the principle cause of the “toxic Strep syndrome” in neutropenic cancer
patients [1–6]. S. mitis/oralis infections have become more difficult for physicians to treat due
to the emergence of penicillin and cephalosporin resistance, as well as intrinsic vancomycin
tolerance [7]. In the process of acquiring such antibiotic resistances, bacterial metabolism
must adapt to facilitate these resistance mechanism(s) [8–11].
The above facts led us to examine the metabolic changes associated with the emergence of DAP-R in S. mitis/oralis [9]. We observed perturbations in glycolysis, the pentose

Antibiotics 2022, 11, 1409. https://doi.org/10.3390/antibiotics11101409

https://www.mdpi.com/journal/antibiotics

Antibiotics 2022, 11, 1409

2 of 13

phosphate pathway, and some amino acid biosynthetic pathways. Changes in glycolysis
are important because VGSs preferentially ferment carbohydrates to generate energy and
biosynthetic intermediates.
Of note, cancer cells commonly exhibit the Warburg effect, specifically by increasing
glucose utilization through glycolysis, with a concomitant decrease in oxidative phosphorylation [12,13]. To maintain their redox poise, cancer cells shunt pyruvate through lactate
dehydrogenase (LDH). In other words, the fermentative metabolism of S. mitis/oralis is very
similar to that of cancer cells. OXA, a pyruvate analog that is a competitive inhibitor of LDH,
is being investigated as an anti-neoplastic drug to inhibit the Warburg effect [13]. Based on
our recent delineation of S. mitis/oralis metabolism and the changes associated with DAP
resistance [9], we hypothesized that OXA would likely alter growth and susceptibility to
DAP in this VGS subgroup [9].
2. Materials and Methods
2.1. Bacterial Strains
The well-characterized DAP-S S. mitis/oralis strain, 351, and its in vitro passage–
derived isogenic DAP-R variant, 351-D10, were used in this study [14]. The parental
strain 351 was isolated from the bloodstream of a patient with IE; it is resistant to penicillin
(MIC = 8 µg/mL) and susceptible to ceftriaxone and ceftaroline (MIC = 8 and 0.5 µg/mL,
respectively). Strain 351-D10 was generated following 10 days of in vitro passage with
DAP (16); its penicillin, ceftriaxone, and ceftaroline MICs were 4 (resistant), 4 (susceptible),
and 2 (susceptible) µg/mL, respectively.
2.2. Cultivation Conditions
The cultivation conditions for these strains have been described [15–18]. Briefly, S. mitis/oralis
strains were grown in Bacto Brain Heart Infusion (BHI) medium, BHI + 2 µg/mL D-Glucose
(BHI + glucose), or on blood agar plates (VWR Scientific Radnor, PA, USA) in selected studies.
Bacterial pre-cultures were inoculated (1:10) from overnight cultures into 50 mL of BHI in 50 mL
conical tubes and incubated at 37 ◦ C, without shaking, for 4 h. These exponential-growth-phase
pre-cultures were collected by centrifugation at 4000 rpm and 22 ◦ C and suspended in 1 mL of
culture medium. Primary cultures were inoculated into 50 mL (BHI + glucose) with or without
OXA in 50 mL conical tubes to an absorbance at 600 nm (A600) of 0.16 and incubated at 37 ◦ C.
Cultures were mixed by inversion every 30 min prior to sampling. The A600 and pH were
recorded every 30 min for 5 h.
2.3. Determination of Glucose and Lactate Concentrations in Cultivation Media
Cell-free media were collected hourly by centrifugation, transferred to 1.5 mL microcentrifuge tubes, and stored at −20 ◦ C until use. Glucose and lactate concentrations in the
culture media were quantified from three biological replicates with kits purchased from
R-Biopharm (Glucose Test Kit, #10716251035; and L-Lactic Acid Test Kit, #10139084035).
2.4. Lactate Dehydrogenase (LDH) Assay
Bacteria were cultivated as described; bacteria were harvested hourly by centrifugation
and disrupted by using a Fast Prep instrument (FP120 Thermo Savant). Cell debris was
removed by centrifugation. The cell-free lysate was used for the LDH activity assays (SigmaAldrich MAK066 Kit). LDH activity was measured from three biological replicates. Protein
concentrations were determined by using the Bradford protein assay (Fisher Scientific,
Waltham, MA, USA).
2.5. Minimum Inhibitory Concentrations (MICs)
DAP was obtained from Merck & Co., Inc. (Whitehouse Station, NJ, USA). DAP MIC
testing was performed by the CLSI-recommended broth microdilution techniques, with
50 µg/mL of CaCl2 added to BHI broth (Difco). In addition, BHI agar supplemented
with 5% lysed horse blood (Difco) was used for quantitative agar-plate colony counts.
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DAP MICs were also determined in parallel by standard Etest (Biomerieux) on Mueller–
Hinton agar (MHA) plates (Difco Laboratories Detroit, MI, USA). For VGS, there are no
formal DAP breakpoints; however, streptococcal strains with DAP MICs ≥ 2 µg/mL are
considered as DAP-R [15]. The MICs of OXA against S. mitis/oralis strains 351 and 351-D10
were determined by microbroth dilution methods; no formal breakpoints exist for this
agent. At least three independent microbroth-dilution-based MICs were performed on
distinct days for all agents. The DAP MICs of S. mitis/oralis strains 351 and 351-D10 were
0.5 and >256 µg/mL, respectively, as assessed by both microbroth dilution and ETEST
methodologies (Table 1). Both 351 and 351-D10 strains had identical high MICs to OXA
(Table 1).
Table 1. MICs of 351 and 351 D10 S. mitis/oralis against DAP and OXA.
DAP MIC (µg/mL)
Strains

DAP

OXA

DAP-S 351
DAP-R 351D10

0.5
>256

2048
2048

2.6. Time–Kill Curves
In vitro time–kill curves were performed to determine the bactericidal impacts of DAP
or OXA alone vs. combined DAP + OXA. DAP or OXA were utilized at or below their
respective in vitro MICs (either 0.5 or 1×). As S. mitis/oralis strains are capnophilic and
slow-growing, we utilized an overnight BHI culture, which was diluted to a final initial
inoculum of ~1–2 × 105 CFU/mL (28). At 0, 2, 4, 6, 8, and 24 h post-inoculation, aliquots
were obtained and quantitatively cultured onto agar plates (28, 29). Quantitative data
were calculated as the mean log10 CFU/mL (+/− SD) of surviving counts. A minimum of
three biological replicates were independently performed on separate days. A “bactericidal
effect” was defined as ≥3 log10 CFU/mL reduction in counts relative to the initial inoculum;
a “synergistic effect” was defined as ≥2 log10 CFU/mL reduction in counts at the 24 h
sampling, when comparing the combined DAP + OXA vs. DAP or OXA alone [15,16].
2.7. In Vitro Resensitization to DAP
To assess the potential of OXA to reverse resistance to DAP, strain 351-D10 was serially
passaged for 10 days in the presence of OXA (2048 µg/mL). Three biological replicates were
performed. DAP MICs were then performed as described on these post-passage strains.
2.8. Ex Vivo Simulated Endocarditis Vegetation (SEV) Model
The SEV pharmacokinetic–pharmacodynamic (PK–PD) system has the ability to provide a human-equivalent model of IE, as well as to simulate human antibiotic concentrations
that precisely mimic clinically relevant therapeutic regimens [17–20]. SEVs were prepared
as described [17–20] by mixing cryoprecipitate as the source of fibrin, a platelet suspension
(American Red Cross), aprotinin (Sigma-Aldrich), and a suspension of each S. mitis/oralis
strain-of-interest in separate experiments (final inoculum, ~109 CFU/0.5 g of SEV). This
methodology results in SEVs that contain approximately 3.8–3.9 g/dL of total protein. The
resultant SEV mixture was then clotted by using bovine thrombin in siliconized microcentrifuge tubes (Pfizer, New York City, NY, USA). Infected SEVs were removed from the
tubes and suspended in the chamber model (~250 mL of media) via a sterile monofilament
line. Fresh medium was continuously added (along with DAP and/or OXA), and spent
media were removed from the model via a peristaltic pump (Masterflex, Cole-Parmer
Instrument Company, Chicago, IL, USA) at a rate which was set to simulate the half-lives
of the drugs of interest. For the SEV model, due to the dependency of DAP on calcium for
antimicrobial activity and calcium loss from the media due to calcium binding to albumin,
the media were supplemented to a concentration of 75 µg/mL of CaCl2 , as previously
described [17–20].
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At pre-assigned times over a 48 h exposure period, SEVs were removed from the
chamber model, weighed, homogenized, and quantitatively cultured to determine bacterial
counts. Tryptic soy agar supplemented with 5% lysed sheep’s blood (Difco) was used for
quantitative sub-culturing from the SEV models. To maximize subculture yields, all plates
were incubated in an anaerobic chamber for 18–24 h at 37 ◦ C before performing colony
counts. Bacterial counts were graphed vs. time over 48 h to evaluate potential bactericidal
and synergistic activities of DAP or OXA alone, as well as combination regimens, using the
same metrics as delineated above.
The limit of detection for these samples was 2 log10 CFU/g. To determine the comparative antibacterial activities of the various regimens within SEVs, the results were plotted,
(log10 CFU/g vs. time (h)) via Prism, GraphPad 8.0.0; San Diego, CA, USA).
2.9. Pharmacokinetic (PK) Studies
For the 48 h SEV treatment duration, we utilized PK modeling for human-equivalent
DAP-alone dose regimens (6 mg/kg/; once-daily) vs. DAP + OXA (2 g by continuous infusion). This DAP dose-regimen is the current FDA-approved therapeutic recommendation
for serious infections.
DAP was administered once daily via the chamber’s injection port. The simulated DAP
regimens represented a targeted T1/2 of 8 h at 6 mg/kg/d, with a targeted peak concentration of ~94 µg/mL. OXA was administered by continuous infusion of 2.048 µg/mL based
on the in vitro–defined MICs. Published standard human-achievable and/or therapeutic
blood-level dosage regimens of OXA were used to guide our dosing strategies [17–20]. All
models were performed in duplicate to ensure reproducibility.
Sampling for PK assays was performed by removing 1 mL of chamber fluid media
(through the injection port) from each of the two parallel SEV models at 0, 2, 4, 6, 8, 32, or
48 h, in duplicate, as previously described [20]. DAP PK evaluations were confirmed by
a validated high-performance liquid chromatography (HPLC) assay that conforms to the
guidelines set forth by the College of American Pathologists [17–20]. This technique demonstrated intra-day coefficients of variation of between 0.56% and 7.14% for all DAP standards.
The DAP peak, AUC0–24h and half-life metrics were determined by the trapezoidal method,
utilizing standard PK modeling software (PK analyst version 1.1; MicroMath Scientific
Software, Salt Lake City, UT, USA).
In the SEV model, simulated once-daily DAP dosing at 6 mg/kg achieved a Cmax of
94.23 ± 3.21 µg/mL, AUC0–24h of 1091.03 ± 78.01 (µg/mL), t1/2 of 8.17 ± 0.23 h (targeted
Cmax and t1/2 = 93.9 µg/mL and 8 h, respectively, for DAP) [21,22].
2.10. Pharmacodynamic (PD) Analyses
For PD evaluations, two SEVs were aseptically removed from each model (total = 4 samples)
at 0, 4, 8, 32, and 48 h. Pilot studies confirmed these time points as providing the most consistent
and differential microbiologic readouts, using this S. mitis/oralis strain pair. After weighing, each
SEV was homogenized with trypsin, serially diluted with cold normal saline (to minimize antibiotic carryover), and then plated for quantitative cultures. The same metrics of “bactericidal” and
“synergistic” outcomes as defined above for in vitro assays were employed for SEVs. Graphs
were prepared by using Prism (9.1.0) software.
2.11. Emergence of DAP-R in the SEV Model
The potential emergence of DAP resistance over the 48 h exposures to DAP alone
vs. DAP–OXA combinations within the SEV model was evaluated. Serial SEV isolates
were parallel-plated on antibiotic-free and DAP-containing plates (3 × the baseline MIC
of the parental DAP-S strain). The DAP MICs of colonies detected on DAP-containing
plates were then confirmed by using the above microbroth dilution technique according to
CLSI guidelines.
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3.4. OXA Is Bactericidal against Both DAP-S and DAP-R Strains
As noted above, OXA is growth inhibitory against S. mitis/oralis strains 351 and
351-D10 (Figures 1 and 2). This could be due to its being either bacteriostatic or bactericidal.
To determine which of these possibilities was more likely, in vitro and ex vivo kill curves
were determined for the two strains (Figures 5 and 6). In vitro, OXA alone or combined
with DAP was bactericidal (>3 log10 CFU/mL reductions in counts) against both strains
(Figure 5). Ex vivo, for the DAP-S 351 strain, the combination of DAP + OXA was rapidly
bactericidal and synergistic over the first 32 h of exposure (Figure 6). After 48 h of exposure,
both the OXA alone and the DAP–OXA combination remained bactericidal. In contrast,
for the DAP-R 351-D10 strain, both OXA and DAP–OXA in combination exerted only a
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Figure 6. Comparison of DAP + OXA combinations vs. DAP-alone in SEVs ex vivo. The
data represent the means (+/− SD) from two independent runs with four biological replicates.
Figure 6. Comparison of DAP + OXA combinations vs. DAP-alone in SEVs ex vivo. The data repreCI =
continuous
infusion.
sent the
means
(+/− SD)
from two independent runs with four biological replicates. CI = continuous

infusion.

3.5. OXA Prevents the Emergence of the DAP-Resistance Phenotype

We have shown that altering the metabolic capabilities of S. aureus with targeted
metabolic inhibitors can prevent the emergence of DAP resistance and/or reverse preexisting DAP resistance [10]. To determine if OXA could similarly reverse DAP resistance in
S. mitis/oralis strain 351-D10, strain 351-D10 was cultivated by serial passage with OXA for
10 d, and the DAP MICs were determined. The MICs of strain 351-D10 colonies did not
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change over the 10 d OXA exposure period (data not shown). Similar to the in vitro serial
passage of strain 351-D10, the combination of DAP and OXA in the SEV model did not
reverse DAP resistance (data not shown).
To assess the ability of OXA to prevent the emergence of DAP-R, strain 351 was serially
passaged with DAP (20 µg/mL) or DAP plus OXA, and then DAP MICs were determined.
Following serial passage with DAP +/− OXA, all colonies examined had acquired DAP-R
(data not shown). In contrast, in the SEV model, cultivation of S. mitis/oralis strain 351 with
DAP + OXA over 48 h prevented the emergence of DAP resistance (DAP MIC = 0.5 µg/mL)
seen with DAP-alone exposures (DAP MIC ≥ 64 µg/mL). These data suggest that in vitro
resensitization to DAP and preventing the emergence of DAP resistance are likely to
represent two discrete mechanistic events involving separate metabolic pathways; this
concept is in agreement with our previous observations related to the evolution of DAP
resistance in S. aureus strains (10).
4. Conclusions
S. mitis/oralis has incomplete central metabolism (i.e., it lacks the TCA cycle [9]). This
causes S. mitis/oralis to rely on glycolysis for energy and a limited set of biosynthetic
intermediates, as well as on LDH for redox balance.
This metabolic scenario is similar to that of cancer cells, where the Warburg effect is
common [12]. Targeting cancer cells displaying the Warburg effect with LDH inhibitor has
driven interest in OXA and its derivatives for use as anti-neoplastic drugs [23]. Not only
are cancer cells susceptible to OXA, but, based on our current investigations, fermentative
bacteria, such as S. mitis/oralis are, as well (Figure 4). Of particular importance, OXA not
only synergistically kills DAP-S S. mitis/oralis strains in combination with DAP, but it also
prevents the emergence of DAP resistance in a host-mimicking microenvironment that
simulates a human endovascular infection. This is of note, given the propensity of DAP-S
S. mitis/oralis strains to evolve rapid, high-level, and durable DAP resistance when exposed
to DAP [1].
These data raised the notion that OXA-like compounds could make effective small
molecule inhibitors of S. mitis/oralis and other fermentative bacteria. Of note, the potential
for OXA as an adjunctive treatment is being actively explored in Mycobacterium tuberculosis,
where OXA derivatives are being used to target protein tyrosine phosphatases [24]. As
additional OXA derivatives are developed to treat cancer, it is likely that some of these
compounds may also be effective at killing fermentative bacterial pathogens, such as
S. mitis/oralis.
It should be noted that our study had some important limitations: (i) only a single
strain pair of DAP-S/DAP-R S. mitis/oralis was utilized. A larger strain cohort will be
required to assess the impacts of the OXA more fully and statistically on DAP-resistance
phenotypes; and (ii) our differential in vitro vs. ex vivo findings, which show distinct
outcomes in the host-mimicking ex vivo microenvironment, need in vivo validation in
endovascular infection models (e.g., experimental endocarditis). These studies are still
in progress.
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